We are live on ! Find out more
NBIX icon

Neurocrine Biosciences
NBIX

218 hedge funds and large institutions have $4.7B invested in Neurocrine Biosciences in 2015 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 92 increasing their positions, 72 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

52% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 23

43% more capital invested

Capital invested by funds: $3.29B → $4.7B (+$1.41B)

29% more call options, than puts

Call options by funds: $36.2M | Put options by funds: $28.1M

28% more repeat investments, than reductions

Existing positions increased: 92 | Existing positions reduced: 72

5% more funds holding

Funds holding: 207 → 218 (+11)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

Holders
218
Holders Change
+11
Holders Change %
+5.31%
% of All Funds
5.72%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.1%
New
35
Increased
92
Reduced
72
Closed
23
Calls
$36.2M
Puts
$28.1M
Net Calls
+$8.07M
Net Calls Change
-$28.1M

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$43.9M
2
Citadel Advisors
Citadel Advisors
Florida
+$33.4M
3
SAM
Sectoral Asset Management
Quebec, Canada
+$21.2M
4
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$20.2M
5
JHIU
Janus Henderson Investors US
Colorado
+$19.9M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$66.1M
2
PA
Perceptive Advisors
New York
-$22.7M
3
Jennison Associates
Jennison Associates
New York
-$19.2M
4
TCP
Tourbillon Capital Partners
New York
-$18M
5
Millennium Management
Millennium Management
New York
-$13.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
CSS
176
Cubist Systematic Strategies
Connecticut
$323K -$1.8M -35,360 -86%
QSS
177
Quantitative Systematic Strategies
Florida
$319K +$287K +5,641 New
QIM
178
Quantitative Investment Management
Virginia
$311K -$1.7M -33,500 -86%
Squarepoint
179
Squarepoint
New York
$300K +$269K +5,300 New
Jane Street
180
Jane Street
New York
$295K +$265K +5,216 New
SI
181
Stephens Inc
Arkansas
$289K – – –
Fifth Third Bancorp
182
Fifth Third Bancorp
Ohio
$287K +$196K +3,864 +321%
SGH
183
Schonfeld Group Holdings
New York
$283K +$254K +5,000 New
FAM
184
Fortaleza Asset Management
Illinois
$272K -$6.1K -120 -2%
AIM
185
Ada Investment Management
New York
$271K +$244K +4,793 New
PAM
186
Panagora Asset Management
Massachusetts
$260K – – –
Stifel Financial
187
Stifel Financial
Missouri
$232K +$209K +4,104 New
Lazard Asset Management
188
Lazard Asset Management
New York
$189K -$128K -2,525 -43%
US Bancorp
189
US Bancorp
Minnesota
$145K +$73K +1,437 +128%
Zurich Cantonal Bank
190
Zurich Cantonal Bank
Switzerland
$136K +$65.8K +1,294 +117%
AIM
191
Assured Investment Management
New York
$113K -$499K -9,821 -83%
Federated Hermes
192
Federated Hermes
Pennsylvania
$111K -$601K -11,816 -86%
LTFS
193
Ladenburg Thalmann Financial Services
Florida
$103K -$1.52K -30 -2%
BJ
194
BlackRock Japan
Japan
$88K +$13.1K +258 +20%
Bank of Montreal
195
Bank of Montreal
Ontario, Canada
$82K +$30.1K +592 +69%
MFS
196
MSI Financial Services
Massachusetts
$80K +$5.08K +100 +8%
Envestnet Asset Management
197
Envestnet Asset Management
Illinois
$71K -$7.72K -152 -11%
TRCT
198
Tower Research Capital (TRC)
New York
$65K +$37.9K +746 +188%
ST
199
Spot Trading
Illinois
$48K +$40.7K +801 +1,456%
NCGI
200
Next Century Growth Investors
Minnesota
$33K -$2.35M -46,224 -99%
6 7
8
9 10

NBIX Hedge Fund Activity: Q4 2015 in Review

218 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q4 2015, worth a combined $4.7B — up 43% from $3.29B a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new NBIX positions and 23 closed out — a net gain of 12 holders — while 92 added to existing stakes and 72 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $43.9M. The largest seller was OrbiMed, cutting an estimated $66.1M.

  • 218 institutional investors held Neurocrine Biosciences (NBIX) as of Q4 2015, up from 207 in Q3 2015.
  • Funds reported $4.7B of Neurocrine Biosciences stock for Q4 2015, up 43% quarter-over-quarter.
  • 35 funds opened new Neurocrine Biosciences positions in Q4 2015 and 23 closed out, a net change of +12 holders.
  • The largest Neurocrine Biosciences buyer in Q4 2015 was T. Rowe Price Associates, an estimated $43.9M added.
  • The largest Neurocrine Biosciences seller in Q4 2015 was OrbiMed, an estimated $66.1M sold.

Based on aggregated 13F filings for Q4 2015.